Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Bioverativ Inc (NASDAQ:BIVV) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 12,901 shares of the biotechnology company’s stock, valued at approximately $736,000.
A number of other institutional investors and hedge funds have also bought and sold shares of BIVV. First Trust Advisors LP purchased a new position in Bioverativ during the 3rd quarter valued at $38,238,000. First Quadrant L P CA purchased a new position in Bioverativ during the 3rd quarter valued at $19,310,000. Peregrine Capital Management LLC purchased a new position in Bioverativ during the 3rd quarter valued at $17,643,000. Nationwide Fund Advisors purchased a new position in Bioverativ during the 3rd quarter valued at $17,617,000. Finally, First Manhattan Co. purchased a new position in Bioverativ during the 3rd quarter valued at $6,863,000. Institutional investors own 95.23% of the company’s stock.
Shares of Bioverativ Inc (NASDAQ:BIVV) opened at $50.30 on Tuesday. Bioverativ Inc has a 1-year low of $40.00 and a 1-year high of $64.41.
A number of equities analysts recently issued reports on BIVV shares. Zacks Investment Research cut Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 1st. Royal Bank Of Canada started coverage on Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price objective for the company. Evercore ISI started coverage on Bioverativ in a report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price objective for the company. Deutsche Bank set a $53.00 target price on Bioverativ and gave the stock a “hold” rating in a report on Monday, November 20th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $71.00 target price on shares of Bioverativ in a report on Monday, October 23rd. One analyst has rated the stock with a sell rating, nine have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $60.93.
COPYRIGHT VIOLATION NOTICE: “12,901 Shares in Bioverativ Inc (BIVV) Purchased by Raymond James Financial Services Advisors Inc.” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/05/12901-shares-in-bioverativ-inc-bivv-purchased-by-raymond-james-financial-services-advisors-inc.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
What are top analysts saying about Bioverativ Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bioverativ Inc and related companies.